Is protracted low-dose temozolomide feasible in glioma patients?
Wong
Eric T
ET
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage* / Q000009:adverse effects; D001932:Brain Neoplasms / Q000188:drug therapy*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005240:Feasibility Studies; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008231:Lymphopenia / Q000139:chemically induced*; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide